GLENMARK PHARMACEUTICALS
|
The Current P/S Ratio of GLENMARK PHARMACEUTICALS is 4.01.
| Share Price | ₹2,337.2 | Apr 23,2026 |
| Market Cap | ₹65,955.8 Cr | |
| Sales-TTM | ₹16,468.1 Cr | TTM-Consolidated Results |
| Price/Sales | 4.01x | Calculated as Market Cap/Sales |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of GLENMARK PHARMACEUTICALS
P/S =
Market Capitalization
/
Sales
or, using per-share numbers:
P/S = Stock Price / Sales Per Share
Current Market Cap [ ₹65,955.8 Cr] as on Apr 23,2026
(/) Sales [ ₹16,468.1 Cr] based on TTM-Consolidated Results
(=) P/S Ratio [ 4.01x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay '4.01 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of GLENMARK PHARMACEUTICALS !
The chart below summarizes the trend in P/S Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PS (Price/Sales) ratio chart of GLENMARK PHARMACEUTICALS
PS Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 1.78x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 1.2x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 3.26x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2022 of 1.01x.
How does GLENMARK PHARMACEUTICALS 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 16,468.1 | 4.01 | 65,955.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 56,809.1 | 7.09 | 403,052.0 |
| DIVIS LABORATORIES LTD | 10,314.0 | 16.42 | 169,336.0 |
| CIPLA LTD | 28,351.1 | 3.72 | 105,484.0 |
| TORRENT PHARMACEUTICALS LTD | 12,742.0 | 11.01 | 140,311.0 |
| DR REDDYS LABORATORIES LTD | 34,682.2 | 3.21 | 111,264.0 |
| MANKIND PHARMA LTD | 13,914.1 | 6.80 | 94,614.1 |
| ZYDUS LIFESCIENCES LTD | 26,089.3 | 3.65 | 95,300.4 |
| LUPIN LTD | 26,150.5 | 4.09 | 106,989.0 |
| AUROBINDO PHARMA LTD | 33,181.9 | 2.51 | 83,397.3 |
| ABBOTT INDIA LTD | 6,824.1 | 7.92 | 54,021.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs GLENMARK PHARMACEUTICALS 's P/S Ratio
| Top 10 Industry Peers | PS Ratio |
|---|---|
| Min industry PS | 2.51x |
| Max industry PS | 16.42x |
| Median industry PS | 4.09x |
| Average industry PS | 6.40x |
You may also like the below Video Courses